Look for Post-MI Patients Who May Benefit From an Aldosterone Antagonist

You'll hear more buzz about starting an aldosterone antagonist (spironolactone, eplerenone) in eligible post-MI patients.

This isn't new information. We know adding an aldosterone antagonist to post-MI patients with "systolic" heart failure...or HFrEF...reduces mortality. But less than 20% of patients are started on one.

Help close the gap.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals